123 related articles for article (PubMed ID: 19001559)
1. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
Nichols AI; Fatato P; Shenouda M; Paul J; Isler JA; Pedersen RD; Jiang Q; Ahmed S; Patroneva A
J Clin Pharmacol; 2009 Feb; 49(2):219-28. PubMed ID: 19001559
[TBL] [Abstract][Full Text] [Related]
2. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
[TBL] [Abstract][Full Text] [Related]
3. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
[TBL] [Abstract][Full Text] [Related]
4. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
5. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
8. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
10. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.
Boni J; Abbas R; Leister C; Burns J; Jordan R; Hoffmann M; DeMaio W; Hug B
Cancer Chemother Pharmacol; 2009 Jul; 64(2):263-70. PubMed ID: 19015855
[TBL] [Abstract][Full Text] [Related]
11. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Hynes SM; Wickremsinhe E; Zhang W; Decker R; Ott J; Chandler J; Mitchell M
Biopharm Drug Dispos; 2015 Jan; 36(1):49-63. PubMed ID: 25296725
[TBL] [Abstract][Full Text] [Related]
13. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
14. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
[TBL] [Abstract][Full Text] [Related]
15. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
[TBL] [Abstract][Full Text] [Related]
16. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
17. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
Tsukada H; Chen YL; Xiao G; Lennek L; Milanovic SM; Worden M; Polhamus DG; Chiu YY; Hopkins SC; Galluppi GR
Clin Pharmacokinet; 2023 Dec; 62(12):1755-1763. PubMed ID: 37882999
[TBL] [Abstract][Full Text] [Related]
18. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
19. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
Oganesian A; Shilling AD; Young-Sciame R; Tran J; Watanyar A; Azam F; Kao J; Leung L
Psychopharmacol Bull; 2009; 42(2):47-63. PubMed ID: 19629022
[TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
